A retrospective study assessing influence of demographic factors (age, gender, ethnicity and deprivation) on the prescribing of the high-efficacy disease-modifying therapies (HE-DMTs) alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS) in Manchester, UK
Latest Information Update: 01 Jun 2022
At a glance
- Drugs Alemtuzumab (Primary) ; Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
Most Recent Events
- 01 Jun 2022 New trial record
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022